Inventiva S.A. (NASDAQ:IVA) shares gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $38.00 to $40.00. The stock had previously closed at $13.93, but opened at $14.49. HC Wainwright currently has a buy rating on the stock. Inventiva shares last traded at $14.49, with a volume of 142 shares trading hands.
The company has a market capitalization of $559.75 million, a PE ratio of -12.33 and a beta of 0.36. The company has a debt-to-equity ratio of 0.10, a quick ratio of 7.78 and a current ratio of 7.81. The firm has a fifty day simple moving average of $12.91 and a 200-day simple moving average of $13.64.
Inventiva (NASDAQ:IVA) last issued its earnings results on Monday, August 2nd. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.27 million during the quarter. As a group, research analysts anticipate that Inventiva S.A. will post -2.05 EPS for the current fiscal year.
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
Recommended Story: How to Invest in Stocks with Increasing Dividends
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.